Longeveron (LGVN)
NASDAQ:LGVN
Want to see LGVN full AI Analyst Report?
Earnings Data
Report Date
Aug 07, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.18Last Year’s EPS
-0.33Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mix of meaningful operational and strategic progress — completed enrollment for ELPIS II, new institutional investors, a strengthened IP and regulatory-designation profile, and modest improvements in expenses and net loss — alongside material challenges: a regulatory setback where the FDA rejected RVEF as a primary endpoint and no agreement on a new primary endpoint while the trial remains ongoing, objective-only efficacy expectations, limited cash runway into Q4 2026, and small absolute revenues. Management is pursuing partnerships and will seek FDA engagement immediately after topline results, but the regulatory uncertainty and near-term financing timeline temper optimism.Company Guidance
Completed ELPIS II Enrollment and Near-Term Data Catalyst
ELPIS II Phase IIb trial enrollment of 40 HLHS patients completed (June prior year); topline readout anticipated in August 2026 — identified as the company's primary near-term catalyst.
New Strategic Capital and Repositioning
Attracted new investment capital from multiple life-sciences funds (Coastlands Capital, Janus Henderson Investors, Logos Capital, Kalehua Capital) and executed a strategic shift toward a capital-efficient, asset-light licensing/partnership model to extend runway and focus on near-term value drivers.
Strong Intellectual Property and Regulatory Designations
Laromestrocel supported by 52 issued patents and 60+ pending worldwide; therapy has received multiple FDA expedited designations (including RMAT, Fast Track, Orphan Drug and Rare Pediatric Disease), reinforcing regulatory positioning.
PDCM Development Pathway Established
IND for laromestrocel in Pediatric Dilated Cardiomyopathy became effective July 2025, enabling advancement directly into a single Phase II registrational trial with planning/preparation in 2026 and potential initiation in 2027.
Clinical Revenue Growth
Total revenue for Q1 2026 was $0.4 million; clinical trial revenue increased to $0.4 million from $0.3 million year-over-year, a 46% increase driven by greater participant demand for the Bahamas Registry Trial.
Expense Discipline and Modest Improvement in Net Loss
General & administrative expenses decreased 7% to $2.7 million and R&D decreased 8% to $2.3 million for Q1 2026 versus prior year; net loss improved 6% to $4.7 million.
LGVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LGVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $0.76 | $0.70 | -7.02% |
Mar 17, 2026 | $0.96 | $0.98 | +1.67% |
Nov 04, 2025 | $0.80 | $0.76 | -4.75% |
Aug 13, 2025 | $0.86 | $0.76 | -12.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Longeveron (LGVN) report earnings?
Longeveron (LGVN) is schdueled to report earning on Aug 07, 2026, Before Open (Confirmed).
What is Longeveron (LGVN) earnings time?
Longeveron (LGVN) earnings time is at Aug 07, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LGVN EPS forecast?
LGVN EPS forecast for the fiscal quarter 2026 (Q2) is -0.18.